Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 602-606

  Kanakry, Jennifer A ^a   Kasamon, Yvette L ^a   Gocke, Christopher D ^b   Tsai, Hua Ling ^b   Davis Sproul, Janice ^a   Ghosh, Nilanjan ^a   Symons, Heather ^a   Bolaños Meade, Javier ^a   Gladstone, Douglas E ^a   Swinnen, Lode J ^a   Luznik, Leo ^a   Fuchs, Ephraim J ^a   Jones, Richard J ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic blood or marrow transplantation; Haploidentical; Peripheral T cell lymphoma; Reduced intensity conditioning; Survival outcomes

Indexed keywords

HLA ANTIGEN;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN TISSUE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84875527567     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.006     Document Type: Article

References (33)

1. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16:2780-2795.
2. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538.
3. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
4. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
5. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012, 26(3):520-526.
6. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.
7. Jacobsen E.D., Kim H.T., Ho V.T., et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011, 22:1608-1613.
8. Hamadani M., Awan F.T., Elder P., et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas: evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008, 14:480-483.
9. Goldberg J.D., Chou J.F., Horwitz S., et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymph 2012, 53:1124-1129.
10. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
11. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
12. Campo E., Swerdlow S.H., Harris N.L., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
13. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
19. Cortese G., Andersen P.K. Competing risks and time-dependent covariates. Biom J 2010, 52:138-158.
20. Murashige N., Kami M., Kishi Y., et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005, 130:561-567.
21. Hishizawa M., Kanda J., Utsunomiya A., et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
22. de Lavallade H., Cassier P.A., Bouabdallah R., et al. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma. Br J Haematol 2008, 142:848-850.
23. Zain J., Palmer J.M., Delioukina M., et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymph 2011, 52:1463-1473.
24. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009, 27:3951-3958.
25. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
26. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
27. Hamadani M., Benson D.M., Hofmeister C.C., et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2009, 15:547-553.
28. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
29. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
30. Munchel A., Kesserwan C., Symons H.J., et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011, 3(Suppl 2):e15.
31. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
32. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279-1287.
33. d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral t-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.